CSL shares are back below $100 after a brutal sell-off. The post Under $100, are CSL shares finally too cheap to ignore?

Australian shares are heading towards a soft gain on Monday morning in Week 22, with a ~10 point advance being tipped in ASX 200 futures as Oz investors look to scoop up cheaper deals across the ...

Bearish drivers for Sanofi based on current data, valuation, sector breadth, and scenario-based downside conditions.

On May 18, Bank of America analyst Travis Steed lowered the firm’s price target on Embecta Corp. (NASDAQ:EMBC) to $3 from $11 ...

The healthcare sector just had its best week in six months.

National Healthcare Properties, Inc. is a real estate investment trust, which engages in acquiring, owning, and managing a diversified portfolio of healthcare real estate assets. It operates through ...

On May 15, Alex Guiliano, CIO of Resonate Wealth Partners, joined BNN Bloomberg to suggest that valuations internationally ...

Novartis outlook for 2027 using current valuation, company guidance, institutional inputs, and scenario-based price ranges.

A lot of investors tend to think about the S&P 500 index as one giant monolith, but I think it becomes much more interesting ...

From broad domestic exposure to global pharma and biotech, these funds cover the healthcare sector's main themes.

In a downbeat year for health care stocks, look for AI to boost these sector names in the second half of 2026.

When it comes to growth stocks, much of the attention often centers around tech. But there are potentially much better ...